Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven immunosuppression, e.g., through CD25⁺ regulatory T cells. We addressed this question in a mouse model of mesothelioma by depleting or reconstituting CD25⁺ reg...
Saved in:
Published in | Cancer Immunology, Immunotherapy Vol. 58; no. 8; pp. 1219 - 1228 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Berlin/Heidelberg : Springer-Verlag
01.08.2009
Springer-Verlag Springer Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven immunosuppression, e.g., through CD25⁺ regulatory T cells. We addressed this question in a mouse model of mesothelioma by depleting or reconstituting CD25⁺ regulatory T cells in combination with two different chemotherapeutic drugs. We found that the efficacy of cyclophosphamide to eradicate established tumors, which has been linked to regulatory T cell depletion, was negated by adoptive transfer of CD25⁺ regulatory T cells. Analysis of post-chemotherapy regulatory T cell populations revealed that cyclophosphamide depleted cycling (Ki-67hi) T cells, including foxp3⁺ regulatory CD4⁺ T cells. Ki-67hi CD4⁺ T cells expressed increased levels of two markers, TNFR2 and ICOS, that have been associated with a maximally suppressive phenotype according to recently published studies. This suggest that cyclophosphamide depletes a population of maximally suppressive regulatory T cells, which may explain its superior anti-tumor efficacy in our model. Our data suggest that regulatory T cell depletion could be used to improve the efficacy of anti-cancer chemotherapy regimens. Indeed, we observed that the drug gemcitabine, which does not deplete cycling regulatory T cells, eradicates established tumors in mice only when CD25⁺ CD4⁺ T cells are concurrently depleted. Cyclophosphamide could be used to achieve regulatory T cell depletion in combination with chemotherapy. |
---|---|
AbstractList | Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven immunosuppression, e.g., through CD25
+
regulatory T cells. We addressed this question in a mouse model of mesothelioma by depleting or reconstituting CD25
+
regulatory T cells in combination with two different chemotherapeutic drugs. We found that the efficacy of cyclophosphamide to eradicate established tumors, which has been linked to regulatory T cell depletion, was negated by adoptive transfer of CD25
+
regulatory T cells. Analysis of post-chemotherapy regulatory T cell populations revealed that cyclophosphamide depleted cycling (Ki-67
hi
) T cells, including foxp3
+
regulatory CD4
+
T cells. Ki-67
hi
CD4
+
T cells expressed increased levels of two markers, TNFR2 and ICOS, that have been associated with a maximally suppressive phenotype according to recently published studies. This suggest that cyclophosphamide depletes a population of maximally suppressive regulatory T cells, which may explain its superior anti-tumor efficacy in our model. Our data suggest that regulatory T cell depletion could be used to improve the efficacy of anti-cancer chemotherapy regimens. Indeed, we observed that the drug gemcitabine, which does not deplete cycling regulatory T cells, eradicates established tumors in mice only when CD25
+
CD4
+
T cells are concurrently depleted. Cyclophosphamide could be used to achieve regulatory T cell depletion in combination with chemotherapy. Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven immunosuppression, e.g., through CD25+ regulatory T cells. We addressed this question in a mouse model of mesothelioma by depleting or reconstituting CD25+ regulatory T cells in combination with two different chemotherapeutic drugs. We found that the efficacy of cyclophosphamide to eradicate established tumors, which has been linked to regulatory T cell depletion, was negated by adoptive transfer of CD25+ regulatory T cells. Analysis of post-chemotherapy regulatory T cell populations revealed that cyclophosphamide depleted cycling (Ki-67hi) T cells, including foxp3+ regulatory CD4+ T cells. Ki-67hi CD4+ T cells expressed increased levels of two markers, TNFR2 and ICOS, that have been associated with a maximally suppressive phenotype according to recently published studies. This suggest that cyclophosphamide depletes a population of maximally suppressive regulatory T cells, which may explain its superior anti-tumor efficacy in our model. Our data suggest that regulatory T cell depletion could be used to improve the efficacy of anti-cancer chemotherapy regimens. Indeed, we observed that the drug gemcitabine, which does not deplete cycling regulatory T cells, eradicates established tumors in mice only when CD25+ CD4+ T cells are concurrently depleted. Cyclophosphamide could be used to achieve regulatory T cell depletion in combination with chemotherapy. Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven immunosuppression, e.g., through CD25+ regulatory T cells. We addressed this question in a mouse model of mesothelioma by depleting or reconstituting CD25+ regulatory T cells in combination with two different chemotherapeutic drugs. We found that the efficacy of cyclophosphamide to eradicate established tumors, which has been linked to regulatory T cell depletion, was negated by adoptive transfer of CD25+ regulatory T cells. Analysis of post-chemotherapy regulatory T cell populations revealed that cyclophosphamide depleted cycling (Ki-67(hi)) T cells, including foxp3+ regulatory CD4+ T cells. Ki-67(hi) CD4+ T cells expressed increased levels of two markers, TNFR2 and ICOS, that have been associated with a maximally suppressive phenotype according to recently published studies. This suggest that cyclophosphamide depletes a population of maximally suppressive regulatory T cells, which may explain its superior anti-tumor efficacy in our model. Our data suggest that regulatory T cell depletion could be used to improve the efficacy of anti-cancer chemotherapy regimens. Indeed, we observed that the drug gemcitabine, which does not deplete cycling regulatory T cells, eradicates established tumors in mice only when CD25+ CD4+ T cells are concurrently depleted. Cyclophosphamide could be used to achieve regulatory T cell depletion in combination with chemotherapy. Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven immunosuppression, e.g., through CD25⁺ regulatory T cells. We addressed this question in a mouse model of mesothelioma by depleting or reconstituting CD25⁺ regulatory T cells in combination with two different chemotherapeutic drugs. We found that the efficacy of cyclophosphamide to eradicate established tumors, which has been linked to regulatory T cell depletion, was negated by adoptive transfer of CD25⁺ regulatory T cells. Analysis of post-chemotherapy regulatory T cell populations revealed that cyclophosphamide depleted cycling (Ki-67hi) T cells, including foxp3⁺ regulatory CD4⁺ T cells. Ki-67hi CD4⁺ T cells expressed increased levels of two markers, TNFR2 and ICOS, that have been associated with a maximally suppressive phenotype according to recently published studies. This suggest that cyclophosphamide depletes a population of maximally suppressive regulatory T cells, which may explain its superior anti-tumor efficacy in our model. Our data suggest that regulatory T cell depletion could be used to improve the efficacy of anti-cancer chemotherapy regimens. Indeed, we observed that the drug gemcitabine, which does not deplete cycling regulatory T cells, eradicates established tumors in mice only when CD25⁺ CD4⁺ T cells are concurrently depleted. Cyclophosphamide could be used to achieve regulatory T cell depletion in combination with chemotherapy. |
Author | Robinson, Bruce W. S Lake, Richard A Currie, Andrew J van der Most, Robbert G Mahendran, Sathish Darabi, Anna Nowak, Anna K Prosser, Amy |
Author_xml | – sequence: 1 fullname: van der Most, Robbert G – sequence: 2 fullname: Currie, Andrew J – sequence: 3 fullname: Mahendran, Sathish – sequence: 4 fullname: Prosser, Amy – sequence: 5 fullname: Darabi, Anna – sequence: 6 fullname: Robinson, Bruce W. S – sequence: 7 fullname: Nowak, Anna K – sequence: 8 fullname: Lake, Richard A |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21631682$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19052741$$D View this record in MEDLINE/PubMed https://lup.lub.lu.se/record/1425340$$DView record from Swedish Publication Index |
BookMark | eNp9ktFu0zAUhiM0xLrBA3ADFhLcBY7t1E64QWhigFSBBN215drHrackDnYy6OvxZLhrtTIukGU5Ov7_L8dH_1lx0ocei-IphdcUQL5JAEywEqAuQbC6bB4UM1rxXKnn9KSYAa-glADVaXGW0nX-YNA0j4pT2sCcyYrOit_LqQuRYNTWGz360BPtRozEbE0bhk1Iw0Z33iKxOGBvE8kKE3ozxYj9uKu2eGsLjkRcT60eQ9ySJTHYtukt0SSGFokLe6Tv12T55fIbK_HXEDGlXQGdQ5NtZZqG22IWHwDE96T1nR-POn-DxGywC-Mmtz1sHxcPnW4TPjmc58XV5Yflxady8fXj54v3i9IIxsaSMdZQQfncGi5rUa_MvKoaBxQanhedN7yytqFMOCMMbYSs68rNrbO21mAlPy8We276icO0UkP0nY5bFbRX7TTkvcpbJVSOS5RcV8ox5Kqi9UrVUoDiFJhEvpK1rTLu3R6XWR1ak6cZdXuPev-m9xu1DjeKUuAgGsiEVwdCDD8mTKPqfNpNTfcYpqQYiJyKmmbhi3-E12GKfR6WYnkgORSwex7di0wMKUV0d61QULu4qX3cVI6b2sVNNdnz7O83HB2HfGXBy4NAJ6NbF3VvfLrTMSo4FTXLOnaYbb7q1xiPHf7v78_3JqeD0uuYwVffGVAOGSukbPgfbhP7uA |
CODEN | CIIMDN |
CitedBy_id | crossref_primary_10_1007_s00262_011_1103_6 crossref_primary_10_1016_j_cyto_2023_156341 crossref_primary_10_3389_fcell_2020_00401 crossref_primary_10_1016_j_cytogfr_2013_01_005 crossref_primary_10_1186_s12967_014_0245_7 crossref_primary_10_3389_fimmu_2015_00588 crossref_primary_10_1038_s41598_017_17000_1 crossref_primary_10_5306_wjco_v8_i1_37 crossref_primary_10_1007_s12307_012_0100_4 crossref_primary_10_3892_ol_2018_9682 crossref_primary_10_1634_theoncologist_2019_0027 crossref_primary_10_18632_oncotarget_15048 crossref_primary_10_1089_omi_2011_0037 crossref_primary_10_1134_S1990519X11060137 crossref_primary_10_2217_imt_12_96 crossref_primary_10_1158_1078_0432_CCR_13_1576 crossref_primary_10_3389_fonc_2020_568059 crossref_primary_10_1155_2010_539519 crossref_primary_10_3389_fphar_2022_858557 crossref_primary_10_1155_2010_798467 crossref_primary_10_3390_cancers14225488 crossref_primary_10_1158_0008_5472_CAN_16_0984 crossref_primary_10_4049_jimmunol_1401894 crossref_primary_10_1007_s00262_016_1935_1 crossref_primary_10_1038_bjc_2012_362 crossref_primary_10_1111_imm_12913 crossref_primary_10_3389_fimmu_2018_02100 crossref_primary_10_4049_jimmunol_0901060 crossref_primary_10_2217_lmt_14_37 crossref_primary_10_1007_s00595_021_02311_8 crossref_primary_10_1016_j_ctrv_2015_11_005 crossref_primary_10_3389_fonc_2022_939249 crossref_primary_10_1016_j_intimp_2011_05_018 crossref_primary_10_3389_fimmu_2018_01170 crossref_primary_10_4049_jimmunol_1502680 crossref_primary_10_1016_j_coi_2015_12_003 crossref_primary_10_1038_s41571_019_0316_z crossref_primary_10_1007_s00280_016_3152_1 crossref_primary_10_1053_j_seminoncol_2015_05_007 crossref_primary_10_1007_s00262_015_1751_z crossref_primary_10_1158_0008_5472_CAN_09_3690 crossref_primary_10_1517_14712591003610622 crossref_primary_10_4049_jimmunol_0903548 crossref_primary_10_1038_mt_2010_224 crossref_primary_10_1080_00365521_2023_2194011 crossref_primary_10_1155_2019_6313242 crossref_primary_10_1371_journal_pone_0085398 crossref_primary_10_1007_s00005_010_0075_0 crossref_primary_10_4161_onci_28247 crossref_primary_10_3389_fimmu_2018_00594 crossref_primary_10_1016_j_clim_2013_07_003 crossref_primary_10_1016_j_molmed_2017_09_007 crossref_primary_10_3390_cancers14112603 crossref_primary_10_1158_2326_6066_CIR_16_0048 crossref_primary_10_1007_s11523_012_0208_y crossref_primary_10_3389_fonc_2019_01509 crossref_primary_10_1016_j_canlet_2012_05_002 crossref_primary_10_1517_14712598_2010_529126 crossref_primary_10_1016_j_celrep_2022_111874 crossref_primary_10_1016_S0007_4551_20_30281_2 crossref_primary_10_3389_fonc_2022_960317 crossref_primary_10_1038_onc_2010_437 crossref_primary_10_1002_eji_201041205 crossref_primary_10_1016_j_canlet_2012_02_034 crossref_primary_10_1038_nrc_2017_42 crossref_primary_10_1080_14737140_2021_1882308 crossref_primary_10_1371_journal_pone_0006982 crossref_primary_10_1007_s12307_012_0122_y crossref_primary_10_1111_j_1365_2567_2011_03460_x crossref_primary_10_1007_s00281_011_0246_z crossref_primary_10_1111_bcp_14355 crossref_primary_10_1016_j_smim_2014_02_002 crossref_primary_10_1007_s00262_009_0734_3 crossref_primary_10_1097_PPO_0000000000000246 crossref_primary_10_1186_1471_2407_11_505 crossref_primary_10_3389_fimmu_2017_01482 crossref_primary_10_1007_s12032_022_01772_2 crossref_primary_10_3390_ijms19041041 crossref_primary_10_1155_2012_890178 crossref_primary_10_1177_1091581818780128 crossref_primary_10_1097_CJI_0b013e3181e032e8 crossref_primary_10_1186_1479_5876_7_102 crossref_primary_10_3389_fcell_2020_00672 crossref_primary_10_3389_fcell_2021_725473 crossref_primary_10_1016_j_gendis_2022_07_024 crossref_primary_10_1200_EDBK_240837 |
Cites_doi | 10.1084/jem.20022227 10.1183/09031936.06.00135305 10.1111/j.0105-2896.2006.00420.x 10.1038/nrc1613 10.1002/eji.200636593 10.1158/1078-0432.CCR-05-0883 10.1158/0008-5472.CAN-05-1797 10.1182/blood-2006-02-002774 10.1016/S0169-5002(99)00030-6 10.1016/j.coi.2004.01.004 10.1016/j.immuni.2008.02.020 10.1146/annurev.immunol.25.022106.141609 10.1016/j.bbrc.2006.03.018 10.1002/ijc.2910470219 10.1172/JCI35180 10.1084/jem.20040179 10.1007/s00262-006-0225-8 10.1084/jem.20020632 10.1002/eji.200324181 10.1517/14656566.8.8.1103 10.1073/pnas.0507454102 10.1517/14656566.5.12.2441 10.1084/jem.20071341 10.1073/pnas.0400214101 10.1084/jem.20042167 10.1182/blood-2004-07-2505 10.1182/blood-2004-06-2410 10.1182/blood-2007-07-099226 10.1158/0008-5472.CAN-04-3344 10.4049/jimmunol.178.7.4089 10.4049/jimmunol.176.5.2722 10.4049/jimmunol.178.4.2155 10.1182/blood.V95.1.212 10.4049/jimmunol.180.10.6467 10.1016/j.coi.2008.05.008 10.4049/jimmunol.180.3.1535 10.4049/jimmunol.181.5.3291 10.4049/jimmunol.180.6.3627 10.4049/jimmunol.179.5.2808 10.4049/jimmunol.180.5.2967 10.4049/jimmunol.133.4.1710 10.1016/j.coi.2008.05.007 10.4049/jimmunol.166.11.6608 |
ContentType | Journal Article |
Copyright | Springer-Verlag 2008 2009 INIST-CNRS Springer-Verlag 2009 |
Copyright_xml | – notice: Springer-Verlag 2008 – notice: 2009 INIST-CNRS – notice: Springer-Verlag 2009 |
DBID | FBQ IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7T5 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P PQEST PQQKQ PQUKI PRINS 5PM ADTPV AOWAS D95 |
DOI | 10.1007/s00262-008-0628-9 |
DatabaseName | AGRIS Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Immunology Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Lunds universitet |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1432-0851 |
EndPage | 1228 |
ExternalDocumentID | oai_lup_lub_lu_se_f37e73a4_f2e3_418b_8760_31027e3b78d4 1729940521 10_1007_s00262_008_0628_9 19052741 21631682 US201301636779 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .55 .86 .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6J9 6NX 78A 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHVE ACHXU ACIGE ACIHN ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACREN ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFJLC AFKRA AFLOW AFNRJ AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BGNMA BHPHI BPHCQ BVXVI CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FBQ FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IH2 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LK8 LLZTM M1P M4Y M7P MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 X7M YLTOR Z45 Z7U Z7V Z7X Z82 Z83 Z84 Z87 Z8O Z8P Z8V Z8W Z8Y Z91 ZGI ZMTXR ZOVNA ~EX ~KM AAPBV AAUGY H13 IQODW AAEOY AAKKN ABAKF ABEEZ ACACY ACULB ACZOJ AEFQL AFBBN AFGXO AGQEE AGRTI AJOOF ALIPV C24 C6C CGR CUY CVF ECM EIF NPM RPM AAYXX CITATION 7T5 7XB 8FK AZQEC DWQXO GNUQQ H94 K9. PQEST PQUKI PRINS 5PM ADTPV AOWAS D95 |
ID | FETCH-LOGICAL-c622t-222916135dc37868bc5449f0109393915934dd9126fc6c1967884f5dfdd8a0d73 |
IEDL.DBID | RPM |
ISSN | 0340-7004 1432-0851 |
IngestDate | Tue Oct 01 22:30:06 EDT 2024 Tue Sep 17 21:28:21 EDT 2024 Thu Aug 15 23:23:01 EDT 2024 Fri Sep 13 03:19:48 EDT 2024 Thu Sep 12 18:50:19 EDT 2024 Sat Sep 28 08:10:10 EDT 2024 Sun Oct 22 16:05:33 EDT 2023 Sat Dec 16 12:01:34 EST 2023 Wed Dec 27 19:22:05 EST 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Chemotherapy Cyclophosphamide Tumor immunity Gemcitabine Regulatory CD4 Mesothelioma T cells Antineoplastic agent Effectory cell CD4 T lymphocyte Concurrent Eradication Efficiency Immunotherapy T-Lymphocyte Pyrimidine nucleoside Regulatory cell Immune response Malignant tumor Gene expression Tumor necrosis factor receptor 2 Alkylating agent Oxazaphosphinane derivatives Treatment Depletion Antimetabolic Nitrogen mustard Pyrimidine derivatives Suppressive cell Fluorine Organic compounds Cancer |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c622t-222916135dc37868bc5449f0109393915934dd9126fc6c1967884f5dfdd8a0d73 |
Notes | http://dx.doi.org/10.1007/s00262-008-0628-9 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11030690 |
PMID | 19052741 |
PQID | 213520907 |
PQPubID | 48449 |
PageCount | 10 |
ParticipantIDs | swepub_primary_oai_lup_lub_lu_se_f37e73a4_f2e3_418b_8760_31027e3b78d4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11030690 proquest_miscellaneous_20662881 proquest_journals_213520907 crossref_primary_10_1007_s00262_008_0628_9 pubmed_primary_19052741 pascalfrancis_primary_21631682 springer_journals_10_1007_s00262_008_0628_9 fao_agris_US201301636779 |
PublicationCentury | 2000 |
PublicationDate | 2009-08-01 |
PublicationDateYYYYMMDD | 2009-08-01 |
PublicationDate_xml | – month: 08 year: 2009 text: 2009-08-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Heidelberg – name: Germany |
PublicationTitle | Cancer Immunology, Immunotherapy |
PublicationTitleAbbrev | Cancer Immunol Immunother |
PublicationTitleAlternate | Cancer Immunol Immunother |
PublicationYear | 2009 |
Publisher | Berlin/Heidelberg : Springer-Verlag Springer-Verlag Springer Springer Nature B.V |
Publisher_xml | – name: Berlin/Heidelberg : Springer-Verlag – name: Springer-Verlag – name: Springer – name: Springer Nature B.V |
References | Angulo, Gomez de las Heras, Garcia-Bustos, Gargallo, Munoz-Fernandez, Fresno (CR2) 2000; 95 Gonsette (CR16) 2007; 8 Gerdes, Lemke, Baisch, Wacker, Schwab, Stein (CR13) 1984; 133 Awwad, North (CR3) 1989; 49 CR17 Currie, van der Most, Broomfield, Prosser, Tovey, Robinson (CR7) 2008; 180 Stephens, Gray, Anderton (CR40) 2005; 102 Needham, Lee, Beilharz (CR29) 2006; 343 Pelaez, Campillo, Lopez-Asenjo, Subiza (CR34) 2001; 166 Zhou, Levitsky (CR47) 2007; 178 Movahedi, Guilliams, Van den Bossche, Van den Bergh, Gysemans, Beschin, De Baetselier, Van Ginderachter (CR28) 2008; 111 Suzuki, Kapoor, Jassar, Kaiser, Albelda (CR42) 2005; 11 North, Awwad (CR30) 1990; 71 Emens, Jaffee (CR9) 2005; 65 Nowak, Byrne, Millward, Alvarez, Robinson (CR31) 2004; 5 Nowak, Robinson, Lake (CR33) 2003; 63 Marzo, Lake, Robinson, Scott (CR26) 1999; 59 Hegmans, Hemmes, Hammad, Boon, Hoogsteden, Lambrecht (CR18) 2006; 27 Nowak, Robinson, Lake (CR32) 2002; 62 Manning, Whitaker, Murch, Garlepp, Davis, Musk, Robinson (CR25) 1991; 47 Zitvogel, Apetoh, Ghiringhelli, Andre, Tesniere, Kroemer (CR48) 2008; 118 Rudge, Barrett, Scott, van Driel (CR38) 2007; 178 Ghiringhelli, Larmonier, Schmitt, Parcellier, Cathelin, Garrido, Chauffert, Solary, Bonnotte, Martin (CR14) 2004; 34 Piconese, Valzasina, Colombo (CR35) 2008; 205 Beyer, Schultze (CR5) 2006; 108 Herman, Freeman, Mathis, Benoist (CR19) 2004; 199 Kleinewietfeld, Puentes, Borsellino, Battistini, Rotzschke, Falk (CR20) 2005; 105 Miller, van der Most, Akondy, Glidewell, Albott, Masopust, Murali-Krishna, Mahar, Edupuganti, Lalor, Germon, Del Rio, Mulligan, Staprans, Altman, Feinberg, Ahmed (CR27) 2008; 28 Chen, Subleski, Kopf, Howard, Mannel, Oppenheim (CR6) 2008; 180 Andersen, Krarup-Hansen, Martensson, Winther-Nielsen, Thylen, Damgaard, Olling, Wallin (CR1) 1999; 24 den Boer, van Mierlo, Fransen, Melief, Offringa, Toes (CR8) 2005; 65 Ercolini, Ladle, Manning, Pfannenstiel, Armstrong, Machiels, Bieler, Emens, Reilly, Jaffee (CR10) 2005; 201 Kohyama, Sugahara, Sugiyama, Yagita, Okumura, Hozumi (CR21) 2004; 101 Watanabe, Deguchi, Zheng, Tamai, Wang, Cohen, Shu (CR46) 2008; 181 Terabe, Matsui, Park, Mamura, Noben-Trauth, Donaldson, Chen, Wahl, Ledbetter, Pratt, Letterio, Paul, Berzofsky (CR44) 2003; 198 Lohning, Hutloff, Kallinich, Mages, Bonhagen, Radbruch, Hamelmann, Kroczek (CR23) 2003; 197 Simon, Jones, Richards, Wright, Betts, Godkin, Screaton, Gallimore (CR39) 2007; 37 CR45 Taieb, Chaput, Schartz, Roux, Novault, Menard, Ghiringhelli, Terme, Carpentier, Darrasse-Jese, Lemonnier, Zitvogel (CR43) 2006; 176 Strauss, Bergmann, Szczepanski, Lang, Kirkwood, Whiteside (CR41) 2008; 180 Fehervari, Sakaguchi (CR11) 2004; 16 Rabinovich, Gabrilovich, Sotomayor (CR36) 2007; 25 Berzofsky, Terabe (CR4) 2008; 180 Roncarolo, Gregori, Battaglia, Bacchetta, Fleischhauer, Levings (CR37) 2006; 212 Lutsiak, Semnani, De Pascalis, Kashmiri, Schlom, Sabzevari (CR24) 2005; 105 Fernandez, Zeiser, Karsunky, Kambham, Beilhack, Soderstrom, Negrin, Engleman (CR12) 2007; 179 Lake, Robinson (CR22) 2005; 5 Ghiringhelli, Menard, Puig, Ladoire, Roux, Martin, Solary, Le Cesne, Zitvogel, Chauffert (CR15) 2007; 56 AK Nowak (628_CR32) 2002; 62 MG Roncarolo (628_CR37) 2006; 212 RE Gonsette (628_CR16) 2007; 8 S Watanabe (628_CR46) 2008; 181 M Kleinewietfeld (628_CR20) 2005; 105 RJ North (628_CR30) 1990; 71 I Angulo (628_CR2) 2000; 95 M Terabe (628_CR44) 2003; 198 AJ Currie (628_CR7) 2008; 180 B Pelaez (628_CR34) 2001; 166 L Zitvogel (628_CR48) 2008; 118 M Beyer (628_CR5) 2006; 108 AT Boer den (628_CR8) 2005; 65 AM Ercolini (628_CR10) 2005; 201 Z Fehervari (628_CR11) 2004; 16 AK Nowak (628_CR33) 2003; 63 MK Andersen (628_CR1) 1999; 24 J Gerdes (628_CR13) 1984; 133 L Strauss (628_CR41) 2008; 180 M Kohyama (628_CR21) 2004; 101 628_CR17 GA Rabinovich (628_CR36) 2007; 25 S Piconese (628_CR35) 2008; 205 LA Emens (628_CR9) 2005; 65 AE Herman (628_CR19) 2004; 199 LA Stephens (628_CR40) 2005; 102 ME Lutsiak (628_CR24) 2005; 105 I Fernandez (628_CR12) 2007; 179 LS Manning (628_CR25) 1991; 47 G Rudge (628_CR38) 2007; 178 F Ghiringhelli (628_CR14) 2004; 34 DJ Needham (628_CR29) 2006; 343 JP Hegmans (628_CR18) 2006; 27 AK Simon (628_CR39) 2007; 37 JA Berzofsky (628_CR4) 2008; 180 AL Marzo (628_CR26) 1999; 59 AK Nowak (628_CR31) 2004; 5 K Movahedi (628_CR28) 2008; 111 628_CR45 X Chen (628_CR6) 2008; 180 E Suzuki (628_CR42) 2005; 11 M Awwad (628_CR3) 1989; 49 M Lohning (628_CR23) 2003; 197 F Ghiringhelli (628_CR15) 2007; 56 JD Miller (628_CR27) 2008; 28 J Taieb (628_CR43) 2006; 176 G Zhou (628_CR47) 2007; 178 RA Lake (628_CR22) 2005; 5 |
References_xml | – ident: CR45 – volume: 198 start-page: 1741 year: 2003 end-page: 1752 ident: CR44 article-title: Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence publication-title: J Exp Med doi: 10.1084/jem.20022227 contributor: fullname: Berzofsky – volume: 27 start-page: 1086 year: 2006 end-page: 1095 ident: CR18 article-title: Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses publication-title: Eur Respir J doi: 10.1183/09031936.06.00135305 contributor: fullname: Lambrecht – volume: 133 start-page: 1710 year: 1984 end-page: 1715 ident: CR13 article-title: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki–67 publication-title: J Immunol contributor: fullname: Stein – volume: 62 start-page: 2353 year: 2002 end-page: 2358 ident: CR32 article-title: Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy publication-title: Cancer Res contributor: fullname: Lake – volume: 212 start-page: 28 year: 2006 end-page: 50 ident: CR37 article-title: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2006.00420.x contributor: fullname: Levings – volume: 5 start-page: 397 year: 2005 end-page: 405 ident: CR22 article-title: Immunotherapy and chemotherapy—a practical partnership publication-title: Nat Rev Cancer doi: 10.1038/nrc1613 contributor: fullname: Robinson – volume: 179 start-page: 2808 year: 2007 end-page: 2814 ident: CR12 article-title: CD101 surface expression discriminates potency among murine FoxP3+ regulatory T cells publication-title: J Immunol contributor: fullname: Engleman – volume: 178 start-page: 2155 year: 2007 end-page: 2162 ident: CR47 article-title: Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance publication-title: J Immunol contributor: fullname: Levitsky – volume: 95 start-page: 212 year: 2000 end-page: 220 ident: CR2 article-title: Nitric oxide-producing CD11b+Ly-6G(Gr-1)+CD31(ER-MP12)+ cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice publication-title: Blood contributor: fullname: Fresno – volume: 37 start-page: 758 year: 2007 end-page: 767 ident: CR39 article-title: Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity publication-title: Eur J Immunol doi: 10.1002/eji.200636593 contributor: fullname: Gallimore – volume: 11 start-page: 6713 year: 2005 end-page: 6721 ident: CR42 article-title: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0883 contributor: fullname: Albelda – volume: 65 start-page: 8059 year: 2005 end-page: 8064 ident: CR9 article-title: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-1797 contributor: fullname: Jaffee – volume: 181 start-page: 3291 year: 2008 end-page: 3300 ident: CR46 article-title: Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes publication-title: J Immunol contributor: fullname: Shu – volume: 108 start-page: 804 year: 2006 end-page: 811 ident: CR5 article-title: Regulatory T cells in cancer publication-title: Blood doi: 10.1182/blood-2006-02-002774 contributor: fullname: Schultze – volume: 24 start-page: 39 year: 1999 end-page: 43 ident: CR1 article-title: Ifosfamide in malignant mesothelioma: a phase II study publication-title: Lung Cancer doi: 10.1016/S0169-5002(99)00030-6 contributor: fullname: Wallin – volume: 16 start-page: 203 year: 2004 end-page: 208 ident: CR11 article-title: Development and function of CD25+CD4+ regulatory T cells publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2004.01.004 contributor: fullname: Sakaguchi – volume: 178 start-page: 4089 year: 2007 end-page: 4096 ident: CR38 article-title: Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells publication-title: J Immunol contributor: fullname: van Driel – volume: 49 start-page: 1649 year: 1989 end-page: 1654 ident: CR3 article-title: Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells publication-title: Cancer Res contributor: fullname: North – volume: 28 start-page: 710 year: 2008 end-page: 722 ident: CR27 article-title: Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines publication-title: Immunity doi: 10.1016/j.immuni.2008.02.020 contributor: fullname: Ahmed – volume: 25 start-page: 267 year: 2007 end-page: 296 ident: CR36 article-title: Immunosuppressive strategies that are mediated by tumor cells publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.25.022106.141609 contributor: fullname: Sotomayor – volume: 59 start-page: 1071 year: 1999 end-page: 1079 ident: CR26 article-title: T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors publication-title: Cancer Res contributor: fullname: Scott – volume: 343 start-page: 684 year: 2006 end-page: 691 ident: CR29 article-title: Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2006.03.018 contributor: fullname: Beilharz – volume: 47 start-page: 285 year: 1991 end-page: 290 ident: CR25 article-title: Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions publication-title: Int J Cancer doi: 10.1002/ijc.2910470219 contributor: fullname: Robinson – volume: 118 start-page: 1991 year: 2008 end-page: 2001 ident: CR48 article-title: The anticancer immune response: indispensable for therapeutic success? publication-title: J Clin Invest doi: 10.1172/JCI35180 contributor: fullname: Kroemer – volume: 199 start-page: 1479 year: 2004 end-page: 1489 ident: CR19 article-title: CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion publication-title: J Exp Med doi: 10.1084/jem.20040179 contributor: fullname: Benoist – volume: 180 start-page: 2967 year: 2008 end-page: 2980 ident: CR41 article-title: Expression of ICOS on Human Melanoma-Infiltrating CD4+CD25highFoxp3+ T Regulatory Cells: Implications and Impact on Tumor-Mediated Immune Suppression publication-title: J Immunol contributor: fullname: Whiteside – volume: 56 start-page: 641 year: 2007 end-page: 648 ident: CR15 article-title: Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-006-0225-8 contributor: fullname: Chauffert – ident: CR17 – volume: 197 start-page: 181 year: 2003 end-page: 193 ident: CR23 article-title: Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10 publication-title: J Exp Med doi: 10.1084/jem.20020632 contributor: fullname: Kroczek – volume: 34 start-page: 336 year: 2004 end-page: 344 ident: CR14 article-title: CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative publication-title: Eur J Immunol doi: 10.1002/eji.200324181 contributor: fullname: Martin – volume: 63 start-page: 4490 year: 2003 end-page: 4496 ident: CR33 article-title: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors publication-title: Cancer Res contributor: fullname: Lake – volume: 8 start-page: 1103 year: 2007 end-page: 1116 ident: CR16 article-title: Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.8.8.1103 contributor: fullname: Gonsette – volume: 102 start-page: 17418 year: 2005 end-page: 17423 ident: CR40 article-title: CD4+CD25+ regulatory T cells limit the risk of autoimmune disease arising from T cell receptor crossreactivity publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0507454102 contributor: fullname: Anderton – volume: 5 start-page: 2441 year: 2004 end-page: 2449 ident: CR31 article-title: Current chemotherapeutic treatment of malignant pleural mesothelioma publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.5.12.2441 contributor: fullname: Robinson – volume: 166 start-page: 6608 year: 2001 end-page: 6615 ident: CR34 article-title: Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism publication-title: J Immunol contributor: fullname: Subiza – volume: 205 start-page: 825 year: 2008 end-page: 839 ident: CR35 article-title: OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection publication-title: J Exp Med doi: 10.1084/jem.20071341 contributor: fullname: Colombo – volume: 180 start-page: 1535 year: 2008 end-page: 1544 ident: CR7 article-title: Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors publication-title: J Immunol contributor: fullname: Robinson – volume: 101 start-page: 4192 year: 2004 end-page: 4197 ident: CR21 article-title: Inducible costimulator-dependent IL-10 production by regulatory T cells specific for self-antigen publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0400214101 contributor: fullname: Hozumi – volume: 180 start-page: 3627 year: 2008 end-page: 3635 ident: CR4 article-title: NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis publication-title: J Immunol contributor: fullname: Terabe – volume: 180 start-page: 6467 year: 2008 end-page: 6471 ident: CR6 article-title: Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells publication-title: J Immunol contributor: fullname: Oppenheim – volume: 201 start-page: 1591 year: 2005 end-page: 1602 ident: CR10 article-title: Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response publication-title: J Exp Med doi: 10.1084/jem.20042167 contributor: fullname: Jaffee – volume: 105 start-page: 2877 year: 2005 end-page: 2886 ident: CR20 article-title: CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset publication-title: Blood doi: 10.1182/blood-2004-07-2505 contributor: fullname: Falk – volume: 105 start-page: 2862 year: 2005 end-page: 2868 ident: CR24 article-title: Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide publication-title: Blood doi: 10.1182/blood-2004-06-2410 contributor: fullname: Sabzevari – volume: 111 start-page: 4233 year: 2008 end-page: 4244 ident: CR28 article-title: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity publication-title: Blood doi: 10.1182/blood-2007-07-099226 contributor: fullname: Van Ginderachter – volume: 71 start-page: 90 year: 1990 end-page: 95 ident: CR30 article-title: Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma publication-title: Immunology contributor: fullname: Awwad – volume: 65 start-page: 6984 year: 2005 end-page: 6989 ident: CR8 article-title: CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-3344 contributor: fullname: Toes – volume: 176 start-page: 2722 year: 2006 end-page: 2729 ident: CR43 article-title: Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines publication-title: J Immunol contributor: fullname: Zitvogel – volume: 178 start-page: 4089 year: 2007 ident: 628_CR38 publication-title: J Immunol doi: 10.4049/jimmunol.178.7.4089 contributor: fullname: G Rudge – volume: 65 start-page: 6984 year: 2005 ident: 628_CR8 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-3344 contributor: fullname: AT Boer den – volume: 176 start-page: 2722 year: 2006 ident: 628_CR43 publication-title: J Immunol doi: 10.4049/jimmunol.176.5.2722 contributor: fullname: J Taieb – volume: 59 start-page: 1071 year: 1999 ident: 628_CR26 publication-title: Cancer Res contributor: fullname: AL Marzo – volume: 178 start-page: 2155 year: 2007 ident: 628_CR47 publication-title: J Immunol doi: 10.4049/jimmunol.178.4.2155 contributor: fullname: G Zhou – volume: 63 start-page: 4490 year: 2003 ident: 628_CR33 publication-title: Cancer Res contributor: fullname: AK Nowak – volume: 101 start-page: 4192 year: 2004 ident: 628_CR21 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0400214101 contributor: fullname: M Kohyama – volume: 198 start-page: 1741 year: 2003 ident: 628_CR44 publication-title: J Exp Med doi: 10.1084/jem.20022227 contributor: fullname: M Terabe – volume: 95 start-page: 212 year: 2000 ident: 628_CR2 publication-title: Blood doi: 10.1182/blood.V95.1.212 contributor: fullname: I Angulo – volume: 16 start-page: 203 year: 2004 ident: 628_CR11 publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2004.01.004 contributor: fullname: Z Fehervari – volume: 34 start-page: 336 year: 2004 ident: 628_CR14 publication-title: Eur J Immunol doi: 10.1002/eji.200324181 contributor: fullname: F Ghiringhelli – volume: 25 start-page: 267 year: 2007 ident: 628_CR36 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.25.022106.141609 contributor: fullname: GA Rabinovich – volume: 24 start-page: 39 year: 1999 ident: 628_CR1 publication-title: Lung Cancer doi: 10.1016/S0169-5002(99)00030-6 contributor: fullname: MK Andersen – volume: 47 start-page: 285 year: 1991 ident: 628_CR25 publication-title: Int J Cancer doi: 10.1002/ijc.2910470219 contributor: fullname: LS Manning – volume: 5 start-page: 397 year: 2005 ident: 628_CR22 publication-title: Nat Rev Cancer doi: 10.1038/nrc1613 contributor: fullname: RA Lake – volume: 56 start-page: 641 year: 2007 ident: 628_CR15 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-006-0225-8 contributor: fullname: F Ghiringhelli – volume: 28 start-page: 710 year: 2008 ident: 628_CR27 publication-title: Immunity doi: 10.1016/j.immuni.2008.02.020 contributor: fullname: JD Miller – volume: 71 start-page: 90 year: 1990 ident: 628_CR30 publication-title: Immunology contributor: fullname: RJ North – volume: 180 start-page: 6467 year: 2008 ident: 628_CR6 publication-title: J Immunol doi: 10.4049/jimmunol.180.10.6467 contributor: fullname: X Chen – volume: 62 start-page: 2353 year: 2002 ident: 628_CR32 publication-title: Cancer Res contributor: fullname: AK Nowak – ident: 628_CR17 doi: 10.1016/j.coi.2008.05.008 – volume: 108 start-page: 804 year: 2006 ident: 628_CR5 publication-title: Blood doi: 10.1182/blood-2006-02-002774 contributor: fullname: M Beyer – volume: 180 start-page: 1535 year: 2008 ident: 628_CR7 publication-title: J Immunol doi: 10.4049/jimmunol.180.3.1535 contributor: fullname: AJ Currie – volume: 181 start-page: 3291 year: 2008 ident: 628_CR46 publication-title: J Immunol doi: 10.4049/jimmunol.181.5.3291 contributor: fullname: S Watanabe – volume: 65 start-page: 8059 year: 2005 ident: 628_CR9 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-1797 contributor: fullname: LA Emens – volume: 212 start-page: 28 year: 2006 ident: 628_CR37 publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2006.00420.x contributor: fullname: MG Roncarolo – volume: 105 start-page: 2862 year: 2005 ident: 628_CR24 publication-title: Blood doi: 10.1182/blood-2004-06-2410 contributor: fullname: ME Lutsiak – volume: 111 start-page: 4233 year: 2008 ident: 628_CR28 publication-title: Blood doi: 10.1182/blood-2007-07-099226 contributor: fullname: K Movahedi – volume: 37 start-page: 758 year: 2007 ident: 628_CR39 publication-title: Eur J Immunol doi: 10.1002/eji.200636593 contributor: fullname: AK Simon – volume: 180 start-page: 3627 year: 2008 ident: 628_CR4 publication-title: J Immunol doi: 10.4049/jimmunol.180.6.3627 contributor: fullname: JA Berzofsky – volume: 197 start-page: 181 year: 2003 ident: 628_CR23 publication-title: J Exp Med doi: 10.1084/jem.20020632 contributor: fullname: M Lohning – volume: 49 start-page: 1649 year: 1989 ident: 628_CR3 publication-title: Cancer Res contributor: fullname: M Awwad – volume: 201 start-page: 1591 year: 2005 ident: 628_CR10 publication-title: J Exp Med doi: 10.1084/jem.20042167 contributor: fullname: AM Ercolini – volume: 105 start-page: 2877 year: 2005 ident: 628_CR20 publication-title: Blood doi: 10.1182/blood-2004-07-2505 contributor: fullname: M Kleinewietfeld – volume: 27 start-page: 1086 year: 2006 ident: 628_CR18 publication-title: Eur Respir J doi: 10.1183/09031936.06.00135305 contributor: fullname: JP Hegmans – volume: 179 start-page: 2808 year: 2007 ident: 628_CR12 publication-title: J Immunol doi: 10.4049/jimmunol.179.5.2808 contributor: fullname: I Fernandez – volume: 205 start-page: 825 year: 2008 ident: 628_CR35 publication-title: J Exp Med doi: 10.1084/jem.20071341 contributor: fullname: S Piconese – volume: 180 start-page: 2967 year: 2008 ident: 628_CR41 publication-title: J Immunol doi: 10.4049/jimmunol.180.5.2967 contributor: fullname: L Strauss – volume: 11 start-page: 6713 year: 2005 ident: 628_CR42 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-0883 contributor: fullname: E Suzuki – volume: 5 start-page: 2441 year: 2004 ident: 628_CR31 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.5.12.2441 contributor: fullname: AK Nowak – volume: 133 start-page: 1710 year: 1984 ident: 628_CR13 publication-title: J Immunol doi: 10.4049/jimmunol.133.4.1710 contributor: fullname: J Gerdes – volume: 118 start-page: 1991 year: 2008 ident: 628_CR48 publication-title: J Clin Invest doi: 10.1172/JCI35180 contributor: fullname: L Zitvogel – volume: 102 start-page: 17418 year: 2005 ident: 628_CR40 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0507454102 contributor: fullname: LA Stephens – volume: 343 start-page: 684 year: 2006 ident: 628_CR29 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2006.03.018 contributor: fullname: DJ Needham – volume: 199 start-page: 1479 year: 2004 ident: 628_CR19 publication-title: J Exp Med doi: 10.1084/jem.20040179 contributor: fullname: AE Herman – volume: 8 start-page: 1103 year: 2007 ident: 628_CR16 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.8.8.1103 contributor: fullname: RE Gonsette – ident: 628_CR45 doi: 10.1016/j.coi.2008.05.007 – volume: 166 start-page: 6608 year: 2001 ident: 628_CR34 publication-title: J Immunol doi: 10.4049/jimmunol.166.11.6608 contributor: fullname: B Pelaez |
SSID | ssj0042099 ssj0001254 |
Score | 2.3084018 |
Snippet | Tumor cell death potentially engages with the immune system. However, the efficacy of anti-tumor chemotherapy may be limited by tumor-driven immunosuppression,... |
SourceID | swepub pubmedcentral proquest crossref pubmed pascalfrancis springer fao |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 1219 |
SubjectTerms | Adoptive Transfer Animals Antibodies Antigens, Differentiation, T-Lymphocyte - immunology Antigens, Differentiation, T-Lymphocyte - metabolism Antineoplastic agents Biological and medical sciences Cancer and Oncology Cancer och onkologi Cancer Research Cancer therapies CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism Cells Chemotherapy Clinical Medicine Cyclophosphamide Cyclophosphamide - therapeutic use Cytotoxicity Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Gemcitabine Immune system Immunology Immunosuppressive Agents - therapeutic use Immunotherapy Inducible T-Cell Co-Stimulator Protein Kaplan-Meier Estimate Ki-67 Antigen - immunology Ki-67 Antigen - metabolism Klinisk medicin L-Selectin - immunology L-Selectin - metabolism Lymphocyte Depletion Lymphocytes Medical and Health Sciences Medical sciences Medicin och hälsovetenskap Medicine Medicine & Public Health Mesothelioma Mesothelioma - drug therapy Mesothelioma - immunology Mice Mice, Inbred BALB C Mice, Nude Oncology Original Original Article Pharmacology. Drug treatments Receptors, Tumor Necrosis Factor, Type II - immunology Receptors, Tumor Necrosis Factor, Type II - metabolism Regulatory CD4(+) T cells T-Lymphocytes, Regulatory - drug effects T-Lymphocytes, Regulatory - immunology Tumor immunity Tumors |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELb2ISEuiPeWhcUHTqCoie3YCRcEqGWFtBVaWmlvVvyildqmNK1E_x6_jJk8uiqgPeRQe-Q69ngy9nz-hpA3QRkVRJZGyqZFJHwwUe6Ui6TwkkvPuazZ9q9G8nIivt6kN0fkS3cXBmGVnU2sDbUrLZ6R91nCEbERq35h8BDAbvofVj8jTB-FYdY2l8YxOWWJwHjt6afB6Nt1Z5QF3hCtAwoIoIPfXYAzrvlEmWRRjQOQDJb_wSfqOBQlAiaLCsYsNMku_ueN_guq3EdW_2Ihrb9cw4fkQety0o-NjjwiR375mNy7aoPqT8jv8XZRrqlfF649wKN15nBqd3ZerqZltZoWi5nztMmYW1GQgG20baidsBQZvKGwDHTd5LYv1zs6phgVqN7TgiKGkYJ7XDcJvaXj0fCaRf5XA8OFggZXUq6jaruqC0G4bYDOlnSO97Bu5cBEU9C2RXt9bPeUTIaD8efLqE3tEFnJ2CbCLOLga_LUWa4ymRmbCpEHjNPxHDnrcy6cyxMmg5UWrATs1EVIXXAuK2Kn-DNysiyX_oxQk1hjmEhFYi3sNWMTjAcnKLDMxIg96ZG33WzqVcPgofdczfXU6zoTJ0y9znvkDOZbFz_AwurJd4ZxXfBYpVJQdXGgBPvGGAgkMmM9ct5phW4NQaX3atsjr_e1sIJx_IqlL7cggiT8WZb0yPNGg267mccp0gv1SHagW3sB5AY_rFnOpjVHeILp42QOb_-uU8PbTt3x-oNGUw_-Yb5dwWPg0ZXXgSuveCF0YJ5rkWRGwxc11rBPYMpzozInXtw5FOfkfhOTQxjlS3KyWW_9K3DtNuaiXbZ_APfmTbY priority: 102 providerName: ProQuest – databaseName: SpringerLINK - Czech Republic Consortium dbid: AGYKE link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELe2TkK88A0Lg-EHnkCpGtuxE94m1DKBtgdopfFkxY69VmuTKmkkyp_HX8Y5X1XZhLSHPMQ-OY5zOd_57n6H0HsrlLAsCn2hw8Rnxio_TkXqc2Y45YZSXqPtX1zy8xn7ehVeHSDSH11kN8POI1kL6j7XzVkLxK-99ZzAT3qIjkJXlXqAjs6-_Pw27uUvbNmsu2EuM7R2JLjAObjvHJt3jbi3NR3aJHeBkkkJa2WbIhd3aaG3gyl7j-o_6KP1jjV53GQRljXQoQtUuRlWGzXUv2_DQN5jMZ6gR60Ci88ajnuKDkz2DD24aF30z9GfabXKC2yKJG2PA3FdhxzrrV7m63lerufJapEa3NTfLTFQgFGuG6Ao1-rwwKExt7gw1668WF5s8RQ7H0P5CSfYRURiULbrIWHaeHo5-U5886sJ6oWGJkolL_yyWteNQNwOgBcZXrqsrh0dCHwMvLtqk9G2L9BsMp5-PvfbQhG-5oRsfFeTHDRXGqaaiohHSoeMxdZ5_WjsEPBjytI0Dgi3mmuQOWD3MxumNk2jZJQK-hINsjwzxwirQCtFWMgCrcFyHSmrDKhUlkRq5CJZPPSh4xG5bvBAZI_8XH8VWdf1hK8iYw8dAxfJ5BrktZz9IM5LDPovFwK6TvdYqx-MAEHAI-Khk47XZCtWSuikLmxpJDz0ru8FeeDWL8lMXgGJg_SPosBDrxq-3E0zHoUOrMhD0R7H9gQOaXy_J1vMa8TxwBWj4zG8_ceOH3eT-s_rjxv-33vCslrDpeCSpZGWCiNowqQlhkoWRErC_jySYHUQYagSUcpe3-upJ-hh4_FzQZpv0GBTVOYtKI4bddpKir-TmmQz priority: 102 providerName: Springer Nature |
Title | Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy |
URI | https://link.springer.com/article/10.1007/s00262-008-0628-9 https://www.ncbi.nlm.nih.gov/pubmed/19052741 https://www.proquest.com/docview/213520907/abstract/ https://search.proquest.com/docview/20662881 https://pubmed.ncbi.nlm.nih.gov/PMC11030690 https://lup.lub.lu.se/record/1425340 |
Volume | 58 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLbWIaFdEL8XBsUHTqCsie3YKbdStUygTtNopXGyYsfeKrVJ1awS_ff4y3h2klYFxIFDUsV-cp3k2X4v7_P3EHpnhRKWpUkodJKFzFgV9nORh5wZTrmhlHu2_cklv5ixLzfJzRHi7V4YD9rXan5eLJbnxfzOYytXS91rcWK9q8kwdrmxwK3rdVBHUNr66CftlxW3QtYXzO0M9YEEB5yD6zawGXkeUcJJ6OP_nMCw9wSiUeIIXQ5WqY7NSoeZzCp4bLbOd_E3g_RPXOUuuPobEalfvMaP0aPG6sSD-u6eoCNTPEUPJ01c_Rn6Od0syzU26yxvvuFhnzwc661elKu7slrdZct5bnCdNLfCIAGetK7ZnVypI_GGwtLidZ3evlxv8RS7wED1EWfYwRgxWMi-Segtnl6Or0loftRIXCiooSXlOqw2K18Iwk0DeF7ghduKtZeDWRqDwi2bHWTb52g2Hk2HF2GT3SHUnJD70CUSB3OTJrmmIuWp0gljfetCdbTvaOv7lOV5Pybcaq5hogBnndkkt3meZlEu6At0XJSFOUVYxVopwhIWaw3uZqSsMmAHWZKqyMFPAvS-fZtyVZN4yB1ds9cC6ZNxghbIfoBO4X3L7BYmWTn7RlxoF4xWLgRUdQ-UYNcYAYGYpyRAZ61WyGYuqKCSOqxRJAL0dlcLg9g9v6ww5QZEHA9_msYBellr0L6bjUIGKD3QrZ2Aowc_rIFR42nC21ESoA-tGu479Y_bH9WaevAPi80KDgWHrIy0VBhBMyYtMVSyOFUSFtVIgqtAhKFKpDl79f8dPkMndczOwSxfo-P79ca8AdPvXnVhvN8IOKfDuIseDD5__zqC30-jy6vrrp8F4Dwjg1-ir1rY |
link.rule.ids | 230,315,733,786,790,891,12083,12250,21416,27957,27958,31754,31755,33301,33302,33779,33780,41116,41558,42185,42627,43345,43614,43840,52146,52269,53827,53829,74102,74371,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELbYrgRcEM_dsLDrAydQRGI7dsIFAWpVYFuhpSvtzYpftFKblKSV6N_jlzFO0lYFtIccao9cxx6Px5nP3yD0ygklHEuTUOgkD5l1KsyMMCFnllNuKeUN2_5ozIfX7MtNctNhc-oOVrm1iY2hNqX238jfkph6xEYk3i9_hj5plA-udhk0jtAxo3BS6aHjj_3xt6utKWb-XmgTRvCwOfi9DWtGDYso4SRsov-cwKI_2JiOXF56mGRew0i5NsXF_3zQf6GUu3jqX9yjzX41eIgedI4m_tBqxiN0xxaP0d1RF0p_gn5P1ouywrbKTffZDjf5wrHe6Hm5nJb1cpovZsbiNk9ujUECDs-6JXTypZ63GwpLh6s2o31ZbfAE-1hA_Q7n2CMXMTjFTZPQWzwZD65IaH-14FsoaNEkZRXW62VTCMJdA3hW4Lm_fbWXA8OMQccW3aWxzVN0PehPPg3DLqFDqDkhq9DnDgcPkyZGU5HyVOmEscz56BzNPFN9RpkxWUy401yDbYDzOXOJccakeWQEfYZ6RVnYU4RVrJUiLGGx1nDCjJRTFlwfR1IVecRJgF5vZ1MuW94OuWNobqZeNvk3YeplFqBTmG-Z_wC7Kq-_Ex_NBT-VCwFV5wdKsGuMgEDMUxKgs61WyG7513KnrAG62NXCuvXjlxe2XIOIp95P0zhAJ60G7buZRYknFQpQeqBbOwHPCH5YU8ymDTN47JPG8Qze_s1WDfeduuX1-62mHvzDfL2ER8EjaysdFVbQnElHLJUsTpWEfTSScDogwlIlUsOe3zoUF-jecDK6lJefx1_P0P02KueBlC9Qb1Wt7Utw7lbqvFvCfwAYmkzp |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwELbYRVpxQbw3LOz6wAkUbWI7dsIFoWWr5bEVglbamxW_aKW2CU0r0b_HL2PspKkKaA851B65jj0ejzOfv0HolRNKOJZnsdBZGTPrVFwYYWLOLKfcUsoD2_71kF-N2aeb7KajFGo6WOXWJgZDbSrtv5Gfk5R6xEYizl2Hivj6YfCu_hn7BFI-0Npl0zhAd2FTFH6N5hc92oP5G6IhoOABdPB7G-BMAp8o4SQOOABOYPnvbVEHrqw8YLJsYMxcm-zif97ov6DKPrL6Fwtp2LkGD9D9zuXE71sdeYju2MUjdHTdBdUfo9-j9bxaYrssTfcBD4fM4Vhv9KyqJ1VTT8r51FjcZsxtMEjAMVq31E6-1DN4Q2Hl8LLNbV8tN3iEfVSgeYtL7DGMGNzj0CT0Fo-Gg28ktr9aGC4UtLiSahk36zoUgnDXAJ4u8Mzfw9rJgYnGoG3z7vrY5gkaDy5HF1dxl9oh1pyQVeyziIOvSTOjqch5rnTGWOF8nI4WnrO-oMyYIiXcaa7BSsBJnbnMOGPyMjGCPkWHi2phjxFWqVaKsIylWsNZM1FOWXCCHMlV4rEnEXq9nU1ZtwwesudqDlMvQyZOmHpZROgY5luWP8DCyvF34uO64LFyIaDqdE8J-sYICKQ8JxE62WqF7AxBI3u1jdBZXwsr2I9fubDVGkQ8CX-epxF61mrQrptFknl6oQjle7rVC3hu8P2axXQSOMJTnz6OF_D2b7ZquOvULa9_2Wrq3j_M1jU8Ch7ZWOmosIKWTDpiqWRpriTsqImEcwIRliqRG_b81qE4Q0ewduWXj8PPJ-ge-E6kxQe9QIer5dq-BC9vpU7D-v0D-v9Peg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor+eradication+after+cyclophosphamide+depends+on+concurrent+depletion+of+regulatory+T+cells%3A+a+role+for+cycling+TNFR2-expressing+effector-suppressor+T+cells+in+limiting+effective+chemotherapy&rft.jtitle=Cancer+Immunology%2C+Immunotherapy&rft.au=van+der+Most%2C+Robbert+G.&rft.au=Currie%2C+Andrew+J.&rft.au=Mahendran%2C+Sathish&rft.au=Prosser%2C+Amy&rft.date=2009-08-01&rft.issn=0340-7004&rft.eissn=1432-0851&rft.volume=58&rft.issue=8&rft.spage=1219&rft.epage=1228&rft_id=info:doi/10.1007%2Fs00262-008-0628-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00262_008_0628_9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-7004&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-7004&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-7004&client=summon |